Latest news with #ComprehensiveWeightControlCenter
Yahoo
26-05-2025
- Health
- Yahoo
Study directly compares Zepbound and Wegovy for weight-loss results
Weight-loss medications continue to grow in popularity as an anti-obesity tool — but are some more effective than others? The question was explored in a new study published this month in The New England Journal of Medicine. Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds The randomized, controlled trial — called SURMOUNT-5 — included 751 people throughout the U.S. and Puerto Rico who had obesity but not type 2 diabetes. "Doctors, insurance companies and patients are always asking, 'Which drug is more effective?'" said Dr. Louis Aronne, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, in the release. "This study allowed us to do a direct comparison." Read On The Fox News App "The results are consistent with — in fact, almost identical to — what we've seen in trials in which these drugs were evaluated independently," added Aronne, who was a principal investigator in the trial. The study found that tirzepatide achieved greater weight loss, with participants shedding about 50 pounds (20.2% of their body weight). The group taking semaglutide lost an average of 33 pounds or 13.7% of their baseline weight, according to a press release summarizing the study outcome. Overall, 32% of the people taking tirzepatide lost at least 25% of their body weight; semaglutide users lost around 16%. Weight Loss, Diabetes Drugs Can Cause Mood Changes: What To Know About Behavioral Side Effects Tirzepatide users also reported a "greater reduction in waist circumference" than those on semaglutide. The likely reason for tirzepatide's greater effectiveness is that it uses a "dual mechanism of action," according to Aronne. "Whereas semaglutide works by activating receptors for a hormone called glucagon-like peptide 1, or GLP-1, tirzepatide mimics not only GLP-1, but also an additional hormone, glucose-dependent insulinotropic peptide (GIP)," the release stated. "Together, these actions reduce hunger, lower blood-glucose levels and affect fat cell metabolism." Weight-loss Drugs' Impact On Cancer Risk Revealed In New Study Additional trials are actively exploring whether tirzepatide also reduces the risk of heart attack and stroke, a benefit that has been linked to semaglutide. The study was led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian. It was also conducted with the University of Texas McGovern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin and Eli Lilly (maker of Zepbound). The participants all received guidance regarding nutrition and exercise. The reported side effects were very similar for the two drugs, with 44% of people experiencing nausea and 25% having abdominal pain. Weight-loss Drugs To Get Surprising Endorsement From Global Health Giant Dr. Ada Londono, M.D., a board-certified obesity and internal medicine primary care physician with PlushCare — a virtual health platform offering primary care, therapy and weight management services — said she was not surprised by the study's findings. "The results are consistent with prior trials, confirming tirzepatide's advantage over semaglutide's single GLP-1 action," Londono, who is based in New York City, told Fox News Digital. Beyond weight loss, semaglutide has also shown potential benefits for cardiovascular health, sleep apnea and kidney disease, she noted. "These findings highlight the need for continued research to understand tirzepatide's broader health impacts," she said. "It's encouraging to see ongoing studies exploring the full potential of GLP-1 medications beyond weight management." Londono said these treatments can come with side effects. Semaglutide Found To Have Shocking Benefit For Liver Disease Patients In New Study "Most people on these medications only report mild symptoms, but some have experienced more serious reactions, such as pancreatitis," she told Fox News Digital. "This underscores the importance of reviewing your medical history and discussing any concerns with your healthcare provider." The study did have some limitations — chiefly that it was not a blinded analysis and participants knew which medication they were receiving. This could introduce some level of bias, the researchers acknowledged. Londono pointed out that while the study's findings are "promising," it was funded by Eli Lilly, the manufacturer of Zepbound. "This may raise questions about potential conflicts of interest," she said. "Additionally, the open-label design and 72-week duration may limit objectivity and long-term insight." While the study primarily looked at the impact of the medications, experts agreed there are other factors that play a role in successful weight management. "Weight loss is biological, but it's also emotional, and whole-person support can make the difference between short-term results and sustainable health," Dr. Rekha Kumar, chief medical officer at the weight care program Found and a practicing endocrinologist in New York City, told Fox News Digital. Kumar emphasized the importance of working with a physician to choose a weight-loss medication that matches the patient's personal goals and health status. "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver disease," she said. Looking ahead, the researchers plan to investigate new versions of weight-loss drugs, including retatrutide, which mimics the hormones GLP-1, GIP and glucagon, according to the release. Click Here To Sign Up For Our Health Newsletter "Even though drugs like tirzepatide and semaglutide work really well, better than anything we have ever seen, we still have people who don't respond to them," said Aronne. "So, moving forward, we want to keep trying to do better." A spokesperson from Novo Nordisk, the company that makes Wegovy (semaglutide), sent a statement to Fox News Digital. "Across the respective clinical trial programs and in SURMOUNT-5, both Wegovy and Zepbound have demonstrated clinically significant weight reduction," the company said. "It is important to recognize that the comprehensive management of obesity goes beyond weight reduction alone." For more Health articles, visit The spokesperson also pointed out that in a previous trial, adults who were obese or overweight and who took Wegovy along with diet and exercise lost an average of 15.2% of their weight (~35 pounds) at the two-year mark, compared with 2.6% (~6 pounds) for patients taking a article source: Study directly compares Zepbound and Wegovy for weight-loss results
Mid East Info
13-05-2025
- Health
- Mid East Info
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss - Middle East Business News and Information
Participants achieved an average weight loss of 20.2% with tirzepatide vs. 13.7% with semaglutide In key secondary endpoints, tirzepatide was superior to semaglutide across all weight reduction targets and waist circumference reduction Dubai, United Arab Emirates, May, 2025 – A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ≥10% weight loss 81.6% 60.5% Achieved ≥15% weight loss 64.6% 40.1% Achieved ≥20% weight loss 48.4% 27.3% Achieved ≥25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. About SURMOUNT-5: SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of tirzepatide compared with semaglutide in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate tirzepatide's superiority in percent change from baseline in body weight at 72 weeks compared to semaglutide's. About tirzepatide: Tirzepatide is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing. About Lilly: Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Web Release
12-05-2025
- Health
- Web Release
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
By Editor_wr On May 12, 2025 A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ?10% weight loss 81.6% 60.5% Achieved ?15% weight loss 64.6% 40.1% Achieved ?20% weight loss 48.4% 27.3% Achieved ?25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide Outperforms Semaglutide by 47% in Weight Loss Comments are closed.
